Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children
Avy Violari(University of the Witwatersrand), Paul Palumbo(Dartmouth College), Mark F. Cotton(Stellenbosch University), Jane C. Lindsey(Harvard University Press), Harry Moultrie(Universidad Peruana Cayetano Heredia), Patrick Jean‐Philippe(Jackson Foundation), Raziya Bobat(Jacobi Medical Center), Portia Kamthunzi, Elizabeth Petzold(Duke Medical Center), Linda Millar(Frontier Science & Technology Research Foundation, Inc.), Elaine J. Abrams(ICAP Global Health), Hilda Mujuru(University of Zimbabwe), Susan H. Eshleman(Johns Hopkins University), Lynette Purdue(National Institutes of Health), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Michael D. Hughes(Virginia Tech), Werner Schimana(National Institute of Allergy and Infectious Diseases), Sandhya Khadse(B. J. Medical College & Sassoon Hospital), Linda Barlow‐Mosha(MUJHU Research Collaboration)
Cited by 183
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|896